Literature DB >> 2170436

An immunofluorescence assay for the detection of parvovirus B19 IgG and IgM antibodies based on recombinant viral antigen.

C S Brown1, M J van Bussel, A L Wassenaar, A M van Elsacker-Niele, H T Weiland, M M Salimans.   

Abstract

An indirect immunofluorescence assay for serum IgG and IgM antibodies to human parvovirus B19 was established using recombinant B19 viral antigen, the capsid protein VP1, which had been produced in a baculovirus expression system. This protein gives a strong and characteristic signal in the immunofluorescence assay, making it a suitable candidate for this test system. The test results showed a good correlation with results obtained with a solid-phase capture radioimmunoassay (Cohen et al., 1983). 76% of sera from a random selection of blood donors were positive for B19 IgG which agrees with previous findings. The course of the IgM and IgG antibody response to B19 infection could be followed with the immunofluorescence assay by determining the titers of series of sera taken after a recent B19 infection. Investigation of 24 sera containing rubella-specific IgM showed no cross-reactivity with the recombinant B19 VP1 used in this test system. The test described here has the advantage of being based on a renewable source of antigen and will be further evaluated for routine diagnostic use in comparison with radioimmunoassay.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2170436     DOI: 10.1016/0166-0934(90)90007-3

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  12 in total

1.  Parvovirus diagnostics and vaccine production in insect cells.

Authors:  J I Casal
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Two anti-parvovirus B 19 IgM capture assays incorporating a mouse monoclonal antibody specific for B 19 viral capsid proteins VP 1 and VP 2.

Authors:  H J O'Neill; P V Coyle
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Evaluation of four commercial enzyme immunoassays for detection of immunoglobulin M antibodies to human parvovirus B19.

Authors:  T Sloots; P L Devine
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-09       Impact factor: 3.267

4.  Parvovirus infection causing red cell aplasia and leukopenia in rheumatoid arthritis.

Authors:  A M Kamper; M Malbrain; P Zachee; S L Chew
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

5.  Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19.

Authors:  A L Bruu; S A Nordbø
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

6.  Antibodies against structural and nonstructural proteins of human bocavirus in human sera.

Authors:  Reza Shirkoohi; Rika Endo; Nobuhisa Ishiguro; Shinobu Teramoto; Hideaki Kikuta; Tadashi Ariga
Journal:  Clin Vaccine Immunol       Date:  2009-12-02

7.  Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins.

Authors:  C S Brown; J W Van Lent; J M Vlak; W J Spaan
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

8.  Use of recombinant human parvovirus B19 antigens in serological assays.

Authors:  H A Cubie; E E Leslie; S Smith; H J O'Neill; H Hart; B J Cohen; J M Inglis
Journal:  J Clin Pathol       Date:  1993-09       Impact factor: 3.411

Review 9.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

10.  Seroepidemiology of human bocavirus in Hokkaido prefecture, Japan.

Authors:  Rika Endo; Nobuhisa Ishiguro; Hideaki Kikuta; Shinobu Teramoto; Reza Shirkoohi; Xiaoming Ma; Takashi Ebihara; Hiroaki Ishiko; Tadashi Ariga
Journal:  J Clin Microbiol       Date:  2007-08-15       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.